Skip to main content

Advertisement

Table 1 Characteristics and utilization of drugs of uncertain medical benefit

From: Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

Drugs Approved Indication Total Days Supply prescribed in 2014a Total Drug Cost in 2014b Cost/day (Total drug cost/total days’ supply) AlternativesBrand Alternative Generic Alternative
Altoprev (Lovastatin ER) Hyperlipidemia 32,954 512,685 15.56 Rosuvastatin (Crestor)
Lovastatin
Axert (Almotriptan) Migraine 20,433 546,958 26.77 Rizatriptan (Maxalt)
Sumatriptan
Azor (Amlodipine+Olmesartan) Hypertension 11,372,402 64,391,400 5.66 Telmisartan (Micardis)
Irbesartan
Duexis (Ibuprofen+Famotidine) Arthritis 76,607 1,994,159 26.03 Celecoxib (Celebrex)
Ibuprofen
Kombiglyze XR (Saxagliptin+Metformin) Diabetes 4,191,109 39,075,907 9.32 Sitagliptin (Januvia)
Metformin
Vimovo (Naproxen+Esomeprazole) Arthritis 518,280 13,104,735 25.29 Celecoxib (Celebrex)
Naproxen
  1. aTotal days supply for the selected drug in Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use File,
  2. bTotal cost for the selected drug per Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use File